Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
Consumer health in France continues to experience growth in 2023. Due to the pandemic, consumers’ immune systems have been negatively impacted. The French healthcare system remains weak and 2022 and 2023 have faced multiple challenges, including a…
Consumer health in Denmark is registering solid current value growth in 2023, albeit at a slightly slower rate than seen in the latter half of the review period; however, this growth is partly driven by strong inflation, which has resulted in price…
Consumer health in Belgium continues to see steady growth in current value terms in 2023, albeit at a slightly slower pace than in the previous year. Among the most dynamic categories are analgesics, sleep aids (driven by high stress levels among the…
While most categories of analgesics are set to witness decreases in retail volume sales over 2023, this is largely due to spikes in sales in the wake of the Coronavirus (COVID-19) pandemic as stress and anxiety levels increased. In 2023, many…
Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…
Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…
Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…
Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…
Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…
Following strong growth between 2020 and 2022, analgesics saw much more moderate current value growth in 2023 as the COVID-19 pandemic began to wane. Rising inflation as a result of the energy crisis stemming in part from the war in Ukraine is…